Swiss pharmaceutical giant Novartis will watch "very carefully" how the reciprocal tariff policy proposed by the United ...

Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy proposed by the ...

Swiss pharmaceutical giant Novartis (SIX:NOVN) is keeping a close eye on the U.S. tariff policy proposed by the Biden ...

UBS released its annual report on Monday, with executive compensation being the most debated section. The remuneration for ...

The administration of President Donald Trump said on Thursday that the wind-down of a license allowing energy transactions ...

At Novartis, CEO Vas Narasimhan’s overall 2024 pay increased by 6.9% at grant value, reaching 14.2 million Swiss francs ($15.7 million), according to the company’s annual report (PDF).

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

In 2024, Bayer chief Bill Anderson’s total compensation fell about 21% to 8.84 million euros ($9.6 million). The decline ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...